These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://lilliryvl986700.blogcudinti.com/39260024/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide